Business Context and Reporting Period
Company: Capricor Therapeutics, Inc. (CAPR)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2025
Business Overview: Capricor is a clinical-stage biotechnology company focused on developing cell and exosome-based therapeutics, primarily for Duchenne muscular dystrophy (DMD). The lead candidate, deramiocel, is in Phase 3 clinical trials. The company has no approved commercial products and relies on equity financing and collaboration payments for operations.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2025 |
Six Months Ended June 30, 2025 |
Six Months Ended June 30, 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $8,878,315 |
| Net Loss | $(25,910,791) | $(50,302,385) | $(20,793,855) |
| Loss Per Share (Basic/Diluted) | $(0.57) | $(1.10) | $(0.66) |
| Operating Expenses (Total) | $27,719,134 | $52,702,082 | $30,735,436 |
| Cash & Cash Equivalents (Balance) | $23,241,199 (as of June 30, 2025) | ||
| Marketable Securities (Balance) | $99,559,482 (as of June 30, 2025) | ||
| Total Liquidity | $122.8 million (as of June 30, 2025) | ||
| Accumulated Deficit | $(250.1 million) (as of June 30, 2025) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue was $0 for the three and six months ended June 30, 2025, compared to $3.97 million and $8.88 million in the same periods in 2024. The prior year revenue was derived from the recognition of milestone payments and upfront fees from the U.S. Distribution Agreement with Nippon Shinyaku, which were fully recognized by the end of 2024.
- Increased Operating Loss: Net loss for the six months ended June 30, 2025, increased to $50.3 million from $20.8 million in the prior year period. This was driven by a $17.4 million increase in Research and Development (R&D) expenses and a $4.6 million increase in General and Administrative (G&A) expenses.
- R&D Expense Growth: R&D expenses rose 74% year-over-year for the six-month period to $41.0 million. Increases were attributed to higher personnel costs, expanded manufacturing production for deramiocel, and continued clinical trial activities (HOPE-3 and HOPE-2 OLE).
- Liquidity Position: Total cash, cash equivalents, and marketable securities decreased from $151.5 million at December 31, 2024, to $122.8 million at June 30, 2025, primarily due to operating expenditures and capital investments in manufacturing.
Guidance, Outlook, and Risks
Regulatory and Clinical Outlook
- BLA Status: In July 2025, the FDA issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for deramiocel. The CRL stated the application did not meet statutory requirements for substantial evidence of effectiveness and cited outstanding Chemistry, Manufacturing, and Controls (CMC) items.
- Next Steps: Capricor plans to submit a formal response to the CRL and has scheduled a Type A meeting with the FDA for August 2025. The company intends to resubmit the BLA, potentially incorporating data from the HOPE-3 Phase 3 trial (topline results expected Q4 2025) as supportive evidence.
- Manufacturing: The FDA conducted a Pre-License Inspection (PLI) in May 2025. The company has addressed all Form 483 observations, which were deemed acceptable by the FDA.
Financial Outlook
- Burn Rate: The company expects to incur significant expenses and operating losses for the foreseeable future. Management estimates current liquidity will fund operations into the fourth quarter of 2026.
- Capital Needs: Substantial additional capital will be required to fund clinical trials, manufacturing scale-up, and potential commercialization. Future financing may involve equity or debt, potentially resulting in dilution.
Risks and Contingencies
- Legal Proceedings: A putative securities class action was filed on July 17, 2025, and a derivative action was filed on August 1, 2025. Both seek unspecified damages. The company has not recorded material accruals for these contingencies.
- CIRM Loan Conversion: The company elected to convert a $3.4 million CIRM grant award into a loan. Accrued interest could reach up to $7.1 million depending on final loan terms.
- Collaboration Agreements: A Binding Term Sheet for European distribution with Nippon Shinyaku is under negotiation, with a definitive agreement deadline extended to September 30, 2025. No revenue has been recorded for this potential deal.
Investor Verification Checklist
- BLA Resubmission Strategy: Verify the specific content of the response to the FDA CRL and the timeline for the resubmission of the BLA.
- HOPE-3 Trial Data: Monitor the release of topline results from the HOPE-3 Phase 3 trial (expected Q4 2025) to assess if the data will satisfy FDA efficacy requirements.
- Liquidity Runway: Confirm the sufficiency of the $122.8 million cash position against the projected burn rate, especially given the potential need for additional manufacturing inventory buildout.
- Legal Costs: Track the financial impact and management distraction caused by the pending securities class action and derivative lawsuits.
- European Deal Finalization: Verify if the definitive agreement with Nippon Shinyaku for the European region is executed by the September 30, 2025 deadline to secure the potential $20 million upfront payment.